GLP-1 Receptor Agonists: Growing Use, Need, or Benefit?
Updated
Abstract
Semaglutide (Wegovy) is endorsed as first-line therapy for weight management by the American College of Cardiology.
- GLP-1 receptor agonists like semaglutide may improve glycemic control and lead to substantial weight loss.
- Emerging data suggest benefits from semaglutide even in individuals without diabetes.
- Concerns regarding long-term safety include risks of gallbladder disease, pancreatitis, and anesthesia-related complications.
- While pharmacologic options are increasing, traditional management of obesity through lifestyle interventions remains essential.
- There is a call for comprehensive care models that address both physiological and behavioral aspects of obesity.
Simplified